Outset Medical, Inc. (NASDAQ:OM) Receives $10.00 Consensus PT from Brokerages

Outset Medical, Inc. (NASDAQ:OM) has received a consensus recommendation of “Hold” from the five research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $10.00.

A number of brokerages have commented on OM. TD Cowen reaffirmed a “buy” rating on shares of Outset Medical in a research note on Friday, May 8th. BTIG Research decreased their price target on Outset Medical from $17.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Wall Street Zen cut Outset Medical from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a research note on Friday, March 27th.

Outset Medical Price Performance

Shares of Outset Medical stock opened at $4.58 on Friday. The company has a debt-to-equity ratio of 0.87, a current ratio of 6.29 and a quick ratio of 4.97. The business’s 50 day simple moving average is $4.26 and its two-hundred day simple moving average is $4.17. The stock has a market capitalization of $84.91 million, a P/E ratio of -1.10 and a beta of 1.95. Outset Medical has a one year low of $3.00 and a one year high of $21.98.

Outset Medical (NASDAQ:OM) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.04). The company had revenue of $27.86 million during the quarter, compared to analysts’ expectations of $28.90 million. Outset Medical had a negative return on equity of 56.13% and a negative net margin of 63.65%. Analysts forecast that Outset Medical will post -3.82 EPS for the current year.

Insider Buying and Selling

In other news, CFO Renee Gaeta sold 17,672 shares of Outset Medical stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $4.94, for a total value of $87,299.68. Following the sale, the chief financial officer directly owned 113,753 shares in the company, valued at approximately $561,939.82. This trade represents a 13.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 25,337 shares of company stock valued at $115,660. 2.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Outset Medical

Large investors have recently made changes to their positions in the business. Los Angeles Capital Management LLC bought a new stake in shares of Outset Medical in the 4th quarter worth approximately $29,000. Legal & General Group Plc bought a new stake in shares of Outset Medical in the 2nd quarter worth approximately $34,000. BNP Paribas Financial Markets grew its position in shares of Outset Medical by 7,013.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after buying an additional 2,034 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of Outset Medical in the 4th quarter worth approximately $46,000. Finally, HRT Financial LP bought a new stake in shares of Outset Medical in the 4th quarter worth approximately $58,000.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.